Federal Circuit confirms Genzyme patents as invalid

16-06-2016

Federal Circuit confirms Genzyme patents as invalid

Feng Yu / Shutterstock.com

The US Court of Appeals for the Federal Circuit decided on June 14 that the two patents involved in a dispute between Biomarin Pharmaceuticals and Genzyme Therapeutic Products are unpatentable due to being obvious.


US Court of Appeals for the Federal Circuit, Biomarin, Genzyme, patent, Pompe’s disease, GAA, PTAB, Patent Trial and Appeal Board

LSIPR